About: Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.
  • The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib. (en)
Title
  • Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic
  • Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic (en)
skos:prefLabel
  • Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic
  • Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic (en)
skos:notation
  • RIV/00216224:14110/11:00052777!RIV12-MSM-14110___
http://linked.open...avai/predkladatel
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • V
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 197908
http://linked.open...ai/riv/idVysledku
  • RIV/00216224:14110/11:00052777
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • performans status; Advanced NSCLC; erlotinib; Efficacy (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...ontrolniKodProRIV
  • [1E61203B307B]
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...iv/tvurceVysledku
  • Hrnčiarik, Michal
  • Koubková, Leona
  • Kolek, Vítězslav
  • Pešek, Miloš
  • Salajka, František
  • Skřičková, Jana
  • Tomíšková, Marcela
  • Zatloukal, Pavel
  • Coupková, Helena
  • Grygarková, Yvona
  • Roubec, Jaromír
  • Sixtová, Dimka
  • Sticha, Michal
  • Zemanová, Milana
http://localhost/t...ganizacniJednotka
  • 14110
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software